Cargando…

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([(18)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Science Inc 2013
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799289/ https://www.ncbi.nlm.nih.gov/pubmed/24156027 http://dx.doi.org/10.1002/cam4.102

Ejemplares similares

HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells
por: Arreola, Alexandra, et al.
Publicado: (2014)

The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
por: Lim, Aaron R, et al.
Publicado: (2020)

Racial difference in histologic subtype of renal cell carcinoma
por: Olshan, Andrew F, et al.
Publicado: (2013)

FDG-PET/CT findings of a metastatic pituitary tumor
por: Ilkhchoui, Yashar, et al.
Publicado: (2010)

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment
por: Nogova, Lucia, et al.
Publicado: (2020)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
por: Farmaki, Elena, et al.
Publicado: (2023)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Renal cell carcinoma
por: Jonasch, Eric, et al.
Publicado: (2014)

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging
por: Dejust, Sebastien, et al.
Publicado: (2018)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Gross Tumor Delineation in Esophageal Cancer on MRI Compared With (18)F-FDG-PET/CT
por: Vollenbrock, Sophie E., et al.
Publicado: (2019)

Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
por: Rathmell, Kimryn W., et al.
Publicado: (2015)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
por: Bergerot, Cristiane, et al.
Publicado: (2023)

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma
por: Nakajima, Erica, et al.
Publicado: (2017)

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma
por: Nagle, Sarah J, et al.
Publicado: (2015)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

FDG PET or PET/CT in Evaluation of Renal Angiomyolipoma
por: Lin, Chun-Yi, et al.
Publicado: (2013)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

COVID-19 impact on early career investigators: a call for action
por: Levine, Ross L., et al.
Publicado: (2020)

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
por: Cowey, C. Lance, et al.
Publicado: (2020)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

FDG avid pulmonary amyloid nodule in a patient with metastatic renal cell cancer on 18F-FDG PET/CT
por: Lee, Marco Enoch, et al.
Publicado: (2021)

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
por: Karrison, Theodore, et al.
Publicado: (2018)

Comparative study of (18)F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis
por: Ping, Bingqiong, et al.
Publicado: (2015)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2020)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
por: Kelsh, Shelby E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2t5e2m9n11r22hhoefduc6cfnh